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Economic evaluations and diagnostic
testing: An illustrative case study
approach
Sabina Sanghera, Rosanna Orlando, Tracy Roberts
Health Economics Unit, University of Birmingham
Objective: The aim of this study was to present a clear process of synthesizing test accuracy data when conducting economic evaluations of diagnostic tests for health technology assessment (HTA)
assessors and health economists.
Methods: We appraised the methods advocated for using diagnostic test accuracy data in economic evaluations. We used a case study of fetal anemia in which data from a screening test are used in
combination with a confirmatory test.
Results: We developed a step-by-step guide and consider two scenarios: when data on test accuracy from several studies are based on (i) the same test threshold for positivity and (ii) different test
thresholds.
Conclusions: We conclude that each approach has its strengths and limitations. We show that the optimal operating point of the test should be identified to determine the true cost-effectiveness of the
test. We advocate that these issues require a multidisciplinary team of health economists, decision modelers and statisticians.
Keywords: Economic evaluation, Diagnostic tests, Sensitivity and specificity, ROC curve
Tests are used to determine whether a patient has a disease
and requires treatment. As tests cannot correctly identify the
patient’s disease status 100 percent of the time, diagnostic errors
will occur. To assess if a test or combination of tests should
be used in practice, to avoid an inefficient use of healthcare
resources, a model-based economic evaluation is conducted to
compare alternative testing strategies in terms of their relative
costs and clinical effectiveness (1).
The value of any test depends on its diagnostic test accuracy,
which is the ability of the test to differentiate between patients
that have a disease and those that do not (2). It is commonly
presented in terms of sensitivity and specificity.
A consensus toward a uniform approach for incorporating
test accuracy in economic evaluations does not yet exist. Most
economic evaluations of diagnostic tests consider sensitivity
and specificity to be independent which is not always appro-
priate (3). Attempts by others to provide advice on appropriate
methods have typically lacked clarity (4–6). Research into cor-
rectly identifying appropriate diagnostic tests and the threshold
at which they are most cost-effective must be conducted to pre-
vent poor healthcare resource management. Other factors such
as patient compliance and skills in test performance do affect
health outcomes, but test accuracy can be easily addressed.
First, we thank the clinicians, Professor Mark Kilby and Dr. Katie Morris, for their time and
expertise in this complex disease area. Second, we also thank Dr. Pelham Barton for his input on
the decision model and Professor Jon Deeks for offering advice in respect of SROC curves. The
current work was carried out unfunded.
We aim to propose a process of synthesizing evidence and
conducting economic evaluations of diagnostic tests. This study
is divided into two sections. First, we summarize the three main
suggested approaches for handling accuracy data for economic
evaluations, highlighting their advantages and disadvantages.
We incorporate the main advantages to provide a simplified
guide for dealing with the issues. Second, we demonstrate the
use of our guide in a case study of fetal anemia.
SUMMARY OF KEY ISSUES AND TRADE-OFF BETWEEN SENSITIVITY
AND SPECIFICITY
Sensitivity identifies the True Positive Rate (TPR) of a test.
This is the proportion of times the test positively identifies the
true positives (TPs) that do have the disease (7). Specificity is
the proportion of times the test negatively identifies the True
Negatives (TNs) that do not have the disease (7). This is known
as the True Negative Rate (TNR).
Generally diagnostic test results are in the form of contin-
uous, ordinal data, where results are not classified as disease
positive or negative, but are categorized in terms of disease
severity (8). Sensitivity and specificity depend on arbitrary cut-
off (threshold) levels, chosen to categorize a result as positive
and further determine whether a positive result is mild, moder-
ate or severe (8). When single studies identify sensitivity and
specificity for several cutoff values a receiver operating char-
acteristic (ROC) curve of test accuracy for different disease
severity levels could be presented. Similarly, when several stud-
ies use different cutoff levels the data can be combined using a
summary ROC (SROC) curve.
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Zweig and Campbell (9) explained that sensitivity and
specificity are negatively correlated and, therefore, cannot be
considered separately. At individual test thresholds for positiv-
ity both diseased and nondiseased patients would be categorized
as positive (Supplementary Figure 1, which can be viewed on-
line at www.journals.cambridge.org/thc2012073). This occurs
because tests generally do not have 100 percent TPR (sensitiv-
ity) and 100 percent TNR (specificity). As the test threshold
for positivity is lowered, sensitivity will increase and specificity
will decrease. Hence, the number of individuals who are cor-
rectly categorized test positive will increase, but the number of
nondiseased who are correctly identified as negative will de-
crease, resulting in the number of false positives increasing (9).
This indicates that the test accuracy results obtained are linked
to the threshold used in the study (9). The optimal clinical test
threshold would have an appropriate balance between TPR and
TNR (9).
When continuous data are available, it has been argued
that health economics techniques and principles should be used
to identify the test threshold for categorizing a positive result
(4;6;9). This would enable the investigator to identify the test
threshold belonging to the sensitivity and specificity pair at
which the test is most cost-effective. This test threshold is of-
ten referred to as the Optimal Operating Point (OOP). Once
the OOP is identified, it could be entered into the economic
evaluation as the sensitivity and specificity pair for the test.
In reality, the correlation between sensitivity and specificity
is ignored; the OOP is not used because the test threshold is of-
ten, incorrectly, based on one threshold value that has been
chosen to be clinically preferable even though several cutoffs
are available (8). Furthermore, to overcome the limitations of
selecting one threshold, a sensitivity analysis is conducted to
assess uncertainty of results when the sensitivity and specificity
pair is changed. Typically, sensitivity is changed while keep-
ing specificity constant based on the assumption that they are
independent when they are in fact correlated (10;11).
Current Approaches
We identified three proposed methods of conducting economic
evaluations of diagnostic tests. All the approaches agreed that
the OOP for each test should be identified and entered into
the economic evaluation, but the optimal method by which the
OOP should be identified is unclear (4;6). The three methods
identified include the ROC curve, Value of Information (VOI),
and ROTS (which is not an acronym). We will briefly discuss
these approaches and provide some insight as to why there is no
consensus on a uniform approach. The strengths and limitations
of each approach are highlighted in Table 1.
ROC Curve. ROC curves illustrate the range of sensitivity and
specificity pairs that a test can achieve for every test thresh-
old value, and demonstrates the trade-off between the two as
the test threshold for positivity changes (9). The ROC curve
approach involves applying a formula, which incorporates only
the cost implications of test results, and uses this formula to
create a tangent on the ROC curve. The point at which the ROC
curve and the slope meet is the OOP for the test. For further
details on the methodology, see References 4;5;9;12.
VOI. VOI is based on clinical decision analysis and determines
the cost-effectiveness of a test for a range of disease prevalence
values (6). A formula is applied which ensures the optimal net
benefit of a test is identified for a certain prevalence (7). The
results are used to create a tangent on the ROC curve and the
point where the tangent and the ROC curve meet is the OOP.
This process is repeated for a range of disease prevalence values.
For further details on the methodology see Phelps and Mushlin
(6).
Here, the VOI does not stand for the value of reducing un-
certainty in cost-effectiveness analysis as understood by health
economists (4;6). The VOI by Phelps and Mushlin (6) relates to
minimizing uncertainty of population heterogeneity (4).
ROTS. The ROTS approach is an adaptation of the VOI approach
and involves the translation of the ROC curve into the cost-
effectiveness space (4). ROTS assumes a fixed prevalence and
willingness-to-pay (WTP) threshold. ROTS uses nonlinear ex-
pansion to incorporate partial implementation of treatments at
the same time (4). It is assumed that the mean costs and quality-
adjusted life-years (QALYs) for every sensitivity and specificity
pair on the ROC curve is calculated, demonstrating the changes
in costs and effects as the diagnostic threshold is changed. The
mean costs and QALYs of changing the test threshold and trans-
ferring patients from one treatment to another is then plotted
in the cost-effectiveness space. Net monetary benefit (NMB)
isoquants for £30,000 WTP are also plotted (4). The OOP is
identified as the greatest net benefit, similar to the VOI ap-
proach of Phelps and Mushlin. It is asserted that alternative
tests can then be compared based on the cost-effectiveness re-
sults at their OOP (4). For further details on the methodology,
see Laking et al. (4).
Data from Multiple Studies
The approaches discussed previously are based on data from
individual studies and have not considered the incorporation of
data from several studies by meta-analysis. The Bayesian ap-
proach by Sutton et al. (13) incorporates meta-analysis into the
economic evaluation, but the approach is complex, involving
comprehensive decision modeling. The basic principle under-
pinning all the available approaches is similar: In ROTS and
Sutton et al., an ROC curve is generated and the OOP is identi-
fied by determining the sensitivity and specificity pair with the
greatest NMB for a test. Sutton et al. (13). recognize the VOI
approach in their article and discussed their own approach with
the authors of ROTS but chose not to use either approach to
identify the OOP, which may suggest that neither the ROTS nor
VOI are appropriate when a meta-analysis is conducted.
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Table 1. Advantages and Disadvantages of Current Approaches
Approach Advantages Disadvantages Comment
ROC Curve • Optimal method of presenting sensitivity and
specificity data. Illustrates range of sensitivity
and specificity pairs and demonstrates trade-off
• Presented in cost benefit framework: not
preferred by decision-makers
• ROC curve not used to full potential to identify
OOP
Appears to refer to data from a single study
only and does not discuss meta-analyses
Suggested that it can be adapted to net
benefit framework but the method is not
clearly outlined which may have led to its
limited use [2].
VOI by Phelps and Mushlin • Presented in cost-effectiveness analysis and net
monetary benefit framework: preferred
method by decision-makers
• Comprehensive: considers prevalence, assesses
cost-effectiveness and presents a method for
decision-making
• Utilises ROC Curve to identify OOP
• Presented in net-benefit/prevalence space: not
ideal for decision-makers
• Assesses cost-effectiveness according to
changes in prevalence: decision-makers require
results according to current prevalence of
disease; better suited to sensitivity analysis
• Sensitivity analysis is not discussed or
self-explanatory
Appears to refer to data from a single study
only, does not discuss meta-analyses
We believe VOI is a good approach but may
not be widely adopted due to its complexity
ROTS by Laking et al • Presented in cost-effectiveness analysis and net
monetary benefit framework: preferred
method by decision-makers
• Utilises ROC curve to identify OOP – the OOP
should be used when available
• Most intuitive approach
• Computationally complex
• Assumes high level of existing knowledge in
the area
• Sensitivity analysis is only briefly explained
• Claimed to be more in line with
cost-effectiveness analysis. Promotes quality
adjusted life years, which is not always
appropriate for diagnostic testing
Appears to refer to data from a single study
only, does not discuss meta-analyses
The approach appears to address many of the
limitations of the previous two approaches,
but we believe it is overly complex and must
be presented in a more accessible manner
Bayesian approach by
Sutton et al.
• Presented in cost-effectiveness analysis and net
monetary benefit framework: preferred
method by decision-makers
• Utilises ROC Curve to identify OOP – the OOP
should be used when available
• Overly complex: uses comprehensive decision
modelling and thus assumes advanced
statistical knowledge
Integrates economic evaluations and
meta-analyses, does not discuss single
studies
Note. The table shows the advantages and disadvantages of the ROC Curve, VOI, ROTS and the approach by Sutton et al. A pragmatic approach was taken to identify these
advantages and disadvantages based on possible practical reasons for why these approaches may not have been widely adopted.
ROC curve, receiver operating characteristic curve; VOI, value of Information; OOP, optimal operating point; ROTS is not an acronym.
Case Study
Fetal anemia is a condition where the fetus does not receive
enough oxygen. It ranges from mild to severe and can lead to
morbidity and mortality if untreated (14). A question of current
interest is whether the MCA Doppler test, which is a diagnostic
ultrasound test, should be incorporated into the clinical pathway.
The accuracy of theMCADoppler will determine which fetuses
require confirmatory diagnosis using an invasive cordocentesis
test which carries its own risk of mortality. Cordocentesis is per-
formed on all cases that the MCA Doppler identifies as positive
to confirm the need for treatment with intravascular-intrauterine
transfusion (IUT) (15). By incorporating theMCADoppler into
the screening pathway for fetal anemia, the number of avoidable
life-threatening cordocentesis procedures may decline, as only
those patients that are identified to be positive by the Doppler
would receive the cordocentesis and its associated risks.
In this section, we aim to demonstrate the process of syn-
thesizing evidence and conducting economic evaluations of di-
agnostic tests. We use fetal anemia as a case study because
there is no economic evidence for current practice (K. Morris,
personal communication, 2010). For each scenario, we provide
a step-by-step guide that explains the best method to use when
data from both individual and several studies are provided. Our
approach will be a simplified version of ROTS, similar to Sutton
et al., as it is the most intuitive, but will avoid the complexity.
Our guide to conducting economic evaluations of diagnostic
tests is outlined in Table 2.
Diagnostic Testing. The MCA Doppler is a noninvasive ultrasound
device. A test threshold value of 1.29 multiples of the median
(MOM) identifies mild fetal anemia, 1.5 MOM identifies mod-
erate anemia and 1.55 MOM identifies severe anemia (17). A
55 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 29:1, 2013
Sanghera et al.
Table 2. Guide to Conducting Economic Evaluations of Diagnostic Tests
Single study Multiple studies Comment
Study uses one test threshold
to identify abnormal result
• Treat sensitivity and specificity
independently
• Cannot identify OOP
• Enter available sensitivity and specificity
pair for each test into decision model as
convention
• Treat sensitivity and specificity independently
• Cannot identify OOP
• Collate data from each study using traditional
meta-analysis techniques
• Enter overall test accuracy result from meta-analysis
into decision model
• Compare against alternative test
Study uses several different
test thresholds to identify
abnormal result
• Correlation between sensitivity and
specificity is relevant
• Identify the OOP using ROC curve:
Sensitivity and specificity pair with the
greatest NMB
• Enter test accuracy at OOP into decision
model
• Compare against OOP of alternative test
• Correlation between sensitivity and specificity is
relevant
• Collate data from each study using either bivariate
meta-analysis or Hierarchical Summary Receiver
Operating Characteristic (‘HSROC’)
• Identify the OOP using ROC curve: Sensitivity and
specificity pair with the greatest NMB
• Enter test accuracy at OOP into decision model
• Compare against OOP of alternative test
Bivariate meta-analysis or HSROC are
mathematically equivalent and take into
account the correlation between
sensitivity and specificity, unlike
traditional meta-analysis methods. [16]
Note. The table details our guide to conducting economic evaluations of diagnostic tests when data from several or single studies are available and when data on single or several
diagnostic thresholds are available.
OOP, optimal operating point; ROC curve, receiver operating characteristic curve; HSROC, hierarchical summary receiver operating characteristic curve; NMB, net monetary benefit.
test threshold of >1.5 MOM is commonly used and is able to
detect moderate-severe levels of fetal anemia (18). The tests
ability to detect fetal anemia increases as the severity of ane-
mia increases; therefore, the likelihood of incorrect test results
decreases.
METHODS
The model-based economic evaluations are cost-effectiveness
analyses and were conducted from a UK National Health Ser-
vice (NHS) perspective in secondary care. Outcomes are ex-
pressed as “cost per survival” due to difficulties obtaining utility
values in a fetal disease.
Model Structure
A decision tree was developed following consultation with clin-
ical experts.We compared the outcomes of an at-risk population
when they receive the strategy of including the MCA Doppler
screening test against a strategy of invasive cordocentesis testing
only. The decision model (Supplementary Figure 2, which can
be viewed online at www.journals.cambridge.org/thc2012074)
included the costs and impact of treatment.
Assumptions
We considered one cycle of testing and treatment. We assumed
that every fetus has the same risk of developing fetal ane-
mia and those that were identified to have fetal anemia un-
derwent an IUT. We obtained an estimate of the prevalence
of at-risk women from previous literature (15). The model pa-
rameters and risks associated with IUT and cordocentesis are
outlined in Supplementary Table 1, which can be viewed online
at www.journals.cambridge.org/thc2012075 (15;18–23).
Resource Use and Costs
We obtained the cost of conducting the MCA Doppler from the
BirminghamWomen’s Hospital by using a uterine Doppler as a
proxy, due to difficulties obtaining direct cost data for an MCA
Doppler. The cost includes the time spent by the nurse while
conducting the test. As cordocentesis and IUT are more com-
plex, we assumed that a consultant performs these procedures,
and the cost reflects this. We used the cost of an adult blood
transfusion as a proxy for IUT due to difficulties obtaining data.
All costs are expressed in 2009. Discounting was not applied,
as the time horizon was shorter than a year.
ANALYSIS
Scenario 1
In scenario 1, data from several studies that use the same test
threshold to determine a positive result are used. The test thresh-
old of 1.5 MOM is considered across all studies in the review,
as shown in Table 2, there is no trade-off between sensitivity
and specificity, and they may be treated independently. How-
ever, heterogeneity across studies (i.e., disease frequency in
the populations) should be noted as this may introduce bias. A
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Figure 1. The summary receiver operating characteristic (SROC) curve.
traditional random-effects meta-analysis can be conducted and
the pooled meta-analysis results obtained for sensitivity and
specificity at the 1.5 MOM threshold can be used as the input in
the decision model and compared against cordocentesis alone.
We obtained data on the MCA Doppler test accuracy from the
most up-to-date systematic review for fetal anemia (18).
In this scenario, as only one test threshold is used, the true
cost-effectiveness of the test is not determined because the OOP
could not be identified. If evaluations of diagnostic tests are
conducted without identifying the OOP it is likely that a test
may be incorrectly proven to not be cost-effective because its
OOP was not entered into the evaluation.
Scenario 2
In scenario 2, data from several studies that use different test
thresholds are used. As discussed in Table 2, the range of sen-
sitivity and specificity pairs that the test can meet are provided
and the correlation is relevant.We performed the bivariatemeta-
analysis using STATA. The SROC curve, generated from the bi-
variate meta-analysis, was used to identify a range of sensitivity
and specificity pairs that the Doppler can meet as a function of
changing test thresholds (see Figure 1).
As shown in Table 2, to identify the OOP of the Doppler,
specificity values were chosen and the corresponding sensitivity
values were read off the SROC curve. Specificity values were
chosen mainly around the region where the SROC curve bends,
as the changes in sensitivity are greater within this region. The
identified pairs were entered into the decision tree and compared
against each other, instead of against cordocentesis (using the
same model arm for MCA Doppler test as previously), to iden-
tify the OOP for the MCA Doppler as the pair with the greatest
NMB. The OOP could then be entered into the decision model
and compared against cordocentesis alone as previously to de-
termine whether the introduction of the MCA Doppler at its
OOP would be more cost-effective than cordocentesis alone. In
contrast to scenario 2, the true cost-effectiveness of the test can
be determined as the OOP is identified. This scenario is illus-
trative as some data were not derived from a systematic review.
Similarly, when one study uses several thresholds, the above
steps are repeated but a meta-analysis is not required and con-
sequently a ROC curve is generated (discussed in Table 2).
A practical example could not be provided due to difficulties
obtaining patient-level data. In this case, although the true cost-
effectiveness can be determined, there is a lack of reliability as
the OOP is identified from just one study.
RESULTS
Scenario 1
The results of scenario 1, where multiple studies estimated
one threshold, show that the strategy including the Doppler
costs £60 with an effectiveness of 0.988 and an overall NMB
of £19,670. The strategy with cordocentesis alone costs £280,
with an effectiveness of 0.976 and an overall NMB of £19,250
(see Supplementary Table 2, which can be viewed online
at www.journals.cambridge.org/thc2012076). The strategy in-
cluding the 1.5 MOM Doppler dominates the cordocentesis
alone strategy, as it is less costly and more effective. The NMB
results demonstrate that the optimal strategy incorporates the
MCA Doppler as it generates the greatest NMB.
Scenario 2
In scenario 2, where multiple studies estimated different thresh-
olds, the results for each sensitivity and specificity pair of the
MCA Doppler are presented in Table 3. NMB measures were
calculated to easily identify the most cost-effective sensitivity
and specificity pair. The effectiveness values only vary slightly
because a comparison between tests is not made. Little differ-
ence in effectiveness is expected because there is a trade-off
between sensitivity and specificity. The results indicate that the
OOP could be within a range of values. Either a threshold with
sensitivity of 0.925 and specificity of 0.94 or a sensitivity of
0.88 and specificity of 0.95 is the OOP for the MCA Doppler,
as these values both generate the greatest NMB of approxi-
mately £19,710. As there is a minimal difference between the
two NMB, but a large difference between sensitivity (0.925 or
0.88), the greatest test accuracy should be chosen. In this case,
the optimal pair would be 0.925 sensitivity and 0.94 specificity.
Although we cannot identify the OOP with great precision, the
loss from not being too far away is not too great. For the eco-
nomic evaluation, the OOP would be entered into the decision
model and compared against the OOP of an alternative test.
The results are presented in the cost-effectiveness plane
(Supplementary Figure 3, which can be viewed online at
www.journals.cambridge.org/thc2012077). It illustrates that
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Table 3. Results for Sensitivity and Specificity Values from SROC Curve
Sensitivity Specificity Cost Effectiveness NMB
1 0.5 £170 0.983 £19,490
1 0.6 £140 0.984 £19,540
0.93 0.7 £120 0.985 £19,580
0.9 0.8 £90 0.986 £19,630
0.985 0.83 £80 0.987 £19,660
0.98 0.85 £80 0.987 £19,670
0.972 0.88 £70 0.988 £19,680
0.96 0.9 £60 0.988 £19,690
0.94 0.93 £60 0.988 £19,700
0.925 0.94 £50 0.988 £19,710
0.88 0.95 £50 0.988 £19,710
0.755 0.97 £40 0.987 £19,700
0.265 0.99 £30 0.985 £19,660
Note. The table shows the cost and effectiveness (proportion survived) results for the
range of sensitivity and specificity pairs identified from the SROC curve for scenario
2. The NMB is also presented and the emboldened NMB values in the boxes both
represent the sensitivity and specificity pairs with the greatest NMB. A £20,000
decision-maker WTP value for an additional unit of benefit is used to generate the
NMB.
NMB, net monetary benefit; SROC curve, summary receiver operating characteristic
curve; WTP, willingness-to-pay. Monetary values have been rounded to the nearest 10
for appropriateness and presentation purposes
sensitivity 0.925, specificity 0.94 is most cost-effective as it
is the most effective and least costly and demonstrates the range
of values that are marginally less costly and less effective, rep-
resenting the minimal difference between some test accuracy
measures. As the WTP threshold changed from £0 to £50,000
per additional unit of benefit the 0.925, 0.94 pair remained op-
timal, except at £10,000 and £15,000 WTP.
DISCUSSION
This study discussed how to use sensitivity and specificity ap-
propriately in an economic evaluation; a step-by-step guide to
conducting economic evaluations of diagnostic tests was pro-
vided (Table 2); and the approach was illustrated. We have
shown that when several studies estimate one test threshold
(scenario 1), the correlation between sensitivity and specificity
is not significant and a traditional random-effects meta-analysis
can be conducted. The pooled sensitivity and specificity results
can be entered directly into the decision model and compared
against an alternative test.
We further showed that when several studies estimated dif-
ferent test thresholds (scenario 2) the OOP of the test should be
identified. The correlation between sensitivity and specificity
is significant and a bivariate meta-analysis should be used to
account for the correlation. An SROC curve should be used to
identify a range of sensitivity and specificity pairs, which would
be compared against each other in a decision model to identify
the OOP of the test, which is the sensitivity and specificity pair
with the greatest NMB. TheOOP should then be entered into the
decision model and compared against the OOP of an alternative
test. We believe that this is the optimal approach because the
“true” cost-effectiveness of the test can be identified as the OOP
is used in economic evaluations. Finally, we briefly discussed
that, when a single study estimates different test thresholds, the
approach would be similar to scenario 2, but as data from one
study are considered, a meta-analysis is unnecessary and an
ROC curve would be constructed.
The strength of our study is that we have provided a simple
yet comprehensive step-by-step guide to conducting economic
evaluations of diagnostic tests. We have explained explicitly
when sensitivity and specificity can be treated independently
andwhen it is appropriate to use each approach depending on the
available data, which has not been done before. We have taken
the strengths of other approaches, avoided their complexities,
and provided a recommendation that is readily accessible to
health economists.
We were unable to demonstrate our approach when one
study estimates different thresholds due to a lack of data, but
we believe that our explanation of the method was sufficient to
enable a health economist to implement it. Although we could
address the use of probabilistic sensitivity analysis (PSA) to as-
sess the uncertainty of results in scenario 1, our investigations
have shown that PSA cannot be easily implemented when sev-
eral studies are used. In these cases, the correlation between sen-
sitivity and specificity is relevant andmust be taken into account
when specifying distributions for test accuracy parameters. Al-
though we criticized the Bayesian approach by Sutton et al. (13)
for being too complex, we have not been able to identify a better
method for incorporating PSA. Their approach remains the rec-
ommended method when studies estimate a range of test thresh-
olds. When one study estimates several thresholds, the compre-
hensive decision model approach discussed by Sutton et al.
(13) could be applied. This has not been applied before and was
not discussed by Sutton et al. (13) as data from multiple stud-
ies were the focus of their study. Our initial reservation of the
approach by Sutton et al. (13) was due to it requiring advanced
statistical expertise, which may not be within the skill set of a
typical health economist.
A limitation of our approach and that of Sutton et al. (13)
is that, when data on multiple thresholds are combined from
multiple studies, we are unable to translate the results of the
most cost-effective sensitivity and specificity pair into the clin-
ical setting. Although the pair can be identified, the numeri-
cal test threshold that the test would need to be set to in the
clinical setting to detect a positive result cannot be reliably
identified (13). This is because data from different studies are
collated to generate the SROC curve. There will be unquantified
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variability, such as differing study population and sample sizes,
in addition to the variability that we are interested in, of differing
test thresholds (Deeks J, personal communication, 2010). The
reliability would be improved if each study estimated a range of
test thresholds, allowing the ROC curves to be combined. Thus,
the analysis would not be reliant on a single study for just one re-
sult. This issue does not arise when one study estimates a range
of test thresholds because the sensitivity and specificity pairs
for each clinical diagnostic test threshold will have been used
to construct the ROC curve and, therefore, can be identified. If
the OOP lies near one of the known test threshold points on
the curve, further research on test accuracy could be conducted
within this new range of test thresholds.
In summary, we argue that economic evaluations of diag-
nostic tests should not be treated as economic evaluations of
interventions because these evaluations have issues that require
a specific skill set. We attempted to simplify the method for
conducting economic evaluations of diagnostic tests and pro-
vide one method that can be used for alternative scenarios but
reach the conclusion that the method outlined by Sutton et al.
(13) should be used when studies consider multiple test thresh-
olds. The method is best approached using a multidisciplinary
team. In conclusion, the design of the framework for evalu-
ating diagnostic tests will need further refinement. This study
is meant to provide the first step for further investigation into
economic evaluations of diagnostic tests.
This study focuses on test accuracy data from a screening
test which is followed by a confirmatory test. Further research
should outline the appropriate method when several tests are
used in clinical practice, but the method is unlikely to deviate
much from that discussed here. Further research should involve
determining whether it could be possible to identify the numeri-
cal test threshold that matches the sensitivity and specificity pair
on an SROC curve with certainty when bivariate meta-analysis
is conducted. The methods of sensitivity analysis for diagnostic
tests should also be researched to ensure that the methods are
accessible to health economists.
POLICY IMPLICATIONS
If analysts conducting economic evaluations of diagnostic tests
ignore the correlation between sensitivity and specificity and
fail to identify the OOP of a test, the cost-effectiveness results
will be spurious and policy makers will be misinformed. As
highlighted in our case study, if the analysis is conducted incor-
rectly, it could lead to a course of action, such as an invasive
test, that has a high mortality risk. Therefore, the data must be
handled accurately to ensure that correct implications for policy
makers are provided.
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